Valuation: Rezolute, Inc.

Market Cap 489M 422M 397M 361M 679M 46.84B 689M 4.66B 1.83B 23.43B 1.84B 1.8B 78.04B P/E 2026 *
-6.69x
P/E 2027 * -7.2x
Enterprise Value 489M 422M 397M 361M 679M 46.84B 689M 4.66B 1.83B 23.43B 1.84B 1.8B 78.04B EV / Sales 2026 *
-
EV / Sales 2027 * 212x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day-1.39%
1 week+0.32%
Current month-1.80%
1 month+4.16%
3 months+43.06%
6 months+28.22%
Current year+96.40%
1 week 4.44
Extreme 4.44
4.88
1 month 4.4
Extreme 4.395
5.4
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 Tax

Chief Financial Officer

-3,062 0.0035%
7/2/26 Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%+0.32%-29.24%+211.07% 489M
+0.17%+3.62%+70.94%+109.68% 73.25B
+1.73%+16.15%+51.73%+93.89% 61.95B
+0.17%-3.05%+0.99%+491.49% 28.02B
+5.24%+5.33%+57.01%+17.77% 24.15B
+0.77%-0.46%-17.93%-16.30% 23.01B
-0.71%+5.26%+241.94%+427.03% 18.35B
0.00%+5.57%+39.57%-14.30% 19.46B
+3.83%+2.65%+25.00%+592.85% 15.92B
+1.56%+3.67%+40.93%+152.21% 12.96B
Average +1.13%+1.11%+48.09%+206.54% 27.76B
Weighted average by Cap. +1.21%+3.43%+55.90%+168.42%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.87M 1.7M 3.2M 221M 3.25M 21.96M 8.61M 110M 8.65M 8.46M 368M
Net income -72.7M -62.79M -59.08M -53.69M -101M -6.97B -102M -693M -272M -3.48B -273M -267M -11.6B -75.12M -64.88M -61.04M -55.48M -104M -7.2B -106M -716M -281M -3.6B -282M -276M -11.99B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
26-08-18 US$4.635 -0.96% 269,801
26-08-17 US$4.680 +1.74% 535,242
26-08-14 US$4.600 0.00% 657,137
26-08-13 US$4.600 -2.13% 800,613
26-08-12 US$4.700 +1.73% 2,391,287
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.680USD
Average target price
7.667USD
Spread / Average Target
+63.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock